Bright Minds Biosciences
DRUG
74 hedge funds and large institutions have $515M invested in Bright Minds Biosciences in 2025 Q4 according to their latest regulatory filings, with 17 funds opening new positions, 27 increasing their positions, 20 reducing their positions, and 7 closing their positions.
143% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 7
41% more capital invested
Capital invested by funds: $366M → $515M (+$149M)
35% more repeat investments, than reductions
Existing positions increased: 27 | Existing positions reduced: 20
16% more funds holding
Funds holding: 64 → 74 (+10)
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
1.11% less ownership
Funds ownership: 85.76% → 84.64% (-1.1%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
Driehaus Capital Management
Chicago,
Illinois
|
+$18M |
| 2 |
MB
MPM BioImpact
Boston,
Massachusetts
|
+$15.4M |
| 3 |
BlackRock
New York
|
+$10.7M |
| 4 |
IC
Ikarian Capital
Dallas,
Texas
|
+$9.62M |
| 5 |
Millennium Management
New York
|
+$7.87M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CC
Commodore Capital
New York
|
-$32.2M |
| 2 |
SCM
Sio Capital Management
New York
|
-$7.28M |
| 3 |
Point72 Asset Management
Stamford,
Connecticut
|
-$6.37M |
| 4 |
Morgan Stanley
New York
|
-$4.06M |
| 5 |
Walleye Capital
New York
|
-$3.14M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
76
Citadel Advisors
Miami,
Florida
| – | -$393K | -6,476 | Closed |
|
|
SWGC
77
Summit Wealth Group (Colorado)
Colorado Springs,
Colorado
| – | -$418K | -6,149 | Closed |
|
78
Renaissance Technologies
New York
| – | -$212K | -3,500 | Closed |
|
|
GCS
79
Gordian Capital (Singapore)
Singapore
| – | -$72.8K | -1,200 | Closed |
|
|
AAP
80
Arax Advisory Partners
Denver,
Colorado
| – | -$1.46K | -24 | Closed |
|
81
PNC Financial Services Group
Pittsburgh,
Pennsylvania
| – | -$546 | -9 | Closed |
|
DRUG Hedge Fund Activity: Q4 2025 in Review
74 of the 8,229 institutional investors tracked by Wall St. Rank reported a position in Bright Minds Biosciences (DRUG) for Q4 2025, worth a combined $515M — up 41% from $366M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new DRUG positions and 7 closed out — a net gain of 10 holders — while 27 added to existing stakes and 20 trimmed.
The largest buyer was Driehaus Capital Management, opening a new position worth an estimated $18M. The largest seller was Commodore Capital, cutting an estimated $32.2M.
- 74 institutional investors held Bright Minds Biosciences (DRUG) as of Q4 2025, up from 64 in Q3 2025.
- Funds reported $515M of Bright Minds Biosciences stock for Q4 2025, up 41% quarter-over-quarter.
- 17 funds opened new Bright Minds Biosciences positions in Q4 2025 and 7 closed out, a net change of +10 holders.
- The largest Bright Minds Biosciences buyer in Q4 2025 was Driehaus Capital Management, an estimated $18M added.
- The largest Bright Minds Biosciences seller in Q4 2025 was Commodore Capital, an estimated $32.2M sold.
Based on aggregated 13F filings for Q4 2025.